tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Digestive System Fistula D016154 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Polymyositis D017285 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Nocturia D053158 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
López Lago AM et al. Evolution of hepatorenal syndrome after orthotopic liver transplantation: comparative analysis with patients who developed acute renal failure in the early postoperative period of liver transplantation. 2007 Transplant. Proc. pmid:17889176
Borro JM et al. Conversion from cyclosporine to tacrolimus stabilizes the course of lung function in lung transplant recipients with bronchiolitis obliterans syndrome. 2007 Transplant. Proc. pmid:17889206
Crespo M et al. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. 2009 Jul-Aug Transplant. Proc. pmid:19715848
Sancho Calabuig A et al. Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival. 2009 Jul-Aug Transplant. Proc. pmid:19715850
Pascual J et al. One-center comparison between primary immunosuppression based on neoral cyclosporine and tacrolimus for renal transplantation. 2002 Transplant. Proc. pmid:11959200
Ericzon BG Early graft function in liver transplantation patients. 1994 Transplant. Proc. pmid:7527965
Herrero JC et al. Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications. 2002 Transplant. Proc. pmid:11959201
Ricordi C et al. Donor bone marrow cell infusion without recipient cytoablation induces acceptance of rat islet allografts. 1994 Transplant. Proc. pmid:7527967
Japanese study of FK 506 on kidney transplantation: results of late phase II study. 1993 Transplant. Proc. pmid:7679831
Kobayashi M et al. Production of monoclonal antibody against recombinant human FKBP-12 and subcellular localization of FKBP-12 in human mononuclear and polymorphonuclear cells. 1993 Transplant. Proc. pmid:7679832
Grenier FC et al. A whole blood FK 506 assay for the IMx analyzer. 1991 Transplant. Proc. pmid:1721264
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Tomikawa S et al. Immunosuppressive effects of bactobolamine in vitro and in vivo. 1996 Transplant. Proc. pmid:8623223
Rossi G et al. Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. 1998 Transplant. Proc. pmid:9636562
Nakajima H and Oka T The inhibition of T-cell-receptor-induced Fas ligand upregulation by cyclosporine and FK 506. 1996 Transplant. Proc. pmid:8623224
Samuel D et al. Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. 1998 Transplant. Proc. pmid:9636563
Zeevi A et al. Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. 1990 Transplant. Proc. pmid:1689902
Imventarza O et al. Renal transplantation in baboons under FK 506. 1990 Transplant. Proc. pmid:1689903
Garcia C et al. Collaborative Brazilian Pediatric Renal Transplant Registry (CoBrazPed-RTx): A Report From 2004 to 2013. 2015 Transplant. Proc. pmid:26036492
Nakao A et al. Combined effect of donor-specific bone marrow transplantation via portal vein and FK506 on small bowel transplantation in the rat. 2000 Transplant. Proc. pmid:11120044
Alessiani M et al. FK778 and tacrolimus combination therapy to control acute rejection after pig intestinal transplantation. 2006 Jul-Aug Transplant. Proc. pmid:16908288
Undre NA et al. Pharmacokinetics of tacrolimus: clinically relevant aspects. 1999 Transplant. Proc. pmid:10576037
Chen YH et al. Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. 2005 Transplant. Proc. pmid:16387090
Yilmaz A et al. Severe angioedema caused by banana allergy under tacrolimus immunosuppression. 2005 Transplant. Proc. pmid:16387091
Lai WJ et al. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? 2004 Transplant. Proc. pmid:15518744
Troppmann C et al. Perioperative immunosuppression as a critical determinant of early outcome after discordant xenoislet transplantation: a comparative study. 1996 Transplant. Proc. pmid:8623487
Bierer BE et al. FK 506 and rapamycin: molecular probes of T-lymphocyte activation. 1991 Transplant. Proc. pmid:1721296
McKenna BA et al. Tacrolimus (FK 506): a whole blood assay as measured on the Abbott IMx analyzer. 1996 Transplant. Proc. pmid:8623491
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
Wiebe K et al. FK506 rescue therapy in lung transplantation. 1998 Transplant. Proc. pmid:9636613
Colak H et al. Relationship of Interleukin-10 and Transforming Growth Factor-β Levels With Short-Term Graft Function After Kidney Transplantation. 2015 Transplant. Proc. pmid:25964218
Zhao DQ et al. Sirolimus-Based Immunosuppressive Regimens in Renal Transplantation: A Systemic Review. Transplant. Proc. pmid:26915834
Li D et al. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms. 2006 Transplant. Proc. pmid:17112846
Azuma T et al. Study of graft-infiltrating cells in the rat small bowel allograft using low-dose FK 506. 1999 Transplant. Proc. pmid:10578293
Antoniou EA et al. Effect of donor-specific transfusion in combination with FK 506 in rat cardiac allotransplantation. 1999 Transplant. Proc. pmid:10578296
Erickson L et al. Gene expression profiling of acute rejection and mixed lymphocyte reaction with tacrolimus immunosuppression. 2002 Transplant. Proc. pmid:12176407
Abecassis MM et al. Patient outcomes and economics of once-daily tacrolimus in renal transplant patients: results of a modeling analysis. 2008 Transplant. Proc. pmid:18589126
Orita T et al. Effect of FK 506 in combination with prednisolone on the graft-vs-host reaction after small bowel transplantation in rats. 1994 Transplant. Proc. pmid:7518147
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Rintala JM et al. The effect of FK778 on acute rat renal allograft rejection and expression of platelet-derived growth factor and transforming growth factor-beta. 2006 Transplant. Proc. pmid:17098049
Zhou W et al. Calcineurin inhibitors block B-1 cell differentiation: the relevance to immunosuppressive treatment in ABO-incompatible transplantation. 2005 Transplant. Proc. pmid:15919474
Niel OR et al. Long-term glomerular filtration rate in liver allograft recipients according to the type of calcineurin inhibitors. 2009 Transplant. Proc. pmid:19857743
Marin M et al. Factors influencing the onset of diabetes mellitus after kidney transplantation: a single French center experience. 2005 Transplant. Proc. pmid:15919484
Jacques F et al. Comparison of cyclosporine and tacrolimus in combination with rabbit antithymocyte immunoglobulins as induction therapy in cardiac transplantation. 2009 Transplant. Proc. pmid:19857745
Charco R et al. Low incidence of hypercholesterolemia among liver transplant patients under tacrolimus monotherapy immunosuppression. 2002 Transplant. Proc. pmid:12176482
Rabkin JM et al. Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients. 2002 Transplant. Proc. pmid:12176483
Scantlebury VP et al. Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 1995 Transplant. Proc. pmid:7533436
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Dew MA et al. Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. 1991 Transplant. Proc. pmid:1721360
Gordon RD et al. Liver transplantation under cyclosporine: a decade of experience. 1991 Transplant. Proc. pmid:1703339
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Todo S et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. 1991 Transplant. Proc. pmid:1703340
Lyne JC et al. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up. 1997 Feb-Mar Transplant. Proc. pmid:9123015
Bardella MT et al. FK 506 and cyclosporine: effect on D-xylose absorption in pigs with orthotopic liver-small bowel allotransplants. 1996 Transplant. Proc. pmid:8907937
Liu Y et al. Delayed Initiation of Tacrolimus Is Safe and Effective in Renal Transplant Recipients With Delayed and Slow Graft Function. 2018 Transplant. Proc. pmid:30316359
Sugitani A et al. Intestinal neurons in acute and chronic rejection after small bowel transplantation in dogs. 1996 Transplant. Proc. pmid:8907941
Takayama K et al. Hepatocyte growth factor and vascular endothelial growth factor expression in pig-to-primate xenotransplanted hearts. 2000 Transplant. Proc. pmid:10936314
Izbicki G et al. Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine. 2002 Transplant. Proc. pmid:12493439
Shimizu T et al. Clinical and histological analysis of chronic tacrolimus nephrotoxicity in renal allografts. 2008 Transplant. Proc. pmid:18790237
Ushigome H et al. Immunosuppression in cadaveric renal transplant recipients from non-heart-beating donors in a single center. 2002 Transplant. Proc. pmid:12176533
Weir M Impact of immunosuppressive regimes on posttransplant diabetes mellitus. 2001 Transplant. Proc. pmid:11498201
Kaibori M et al. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. 1999 Feb-Mar Transplant. Proc. pmid:10083347
Tsuchimoto S et al. Orthotopic liver transplantation in rats receiving FK506. 1989 Transplant. Proc. pmid:2468208
Rilo HL et al. Effect of FK 506 on function of human islets of Langerhans. 1991 Transplant. Proc. pmid:1721393
Corry RJ et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123457
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Furtado A et al. Local immunosuppression in clinical small bowel transplantation (report of two cases). 2000 Transplant. Proc. pmid:10995910
Alessiani M et al. Pharmacokinetic study of intraarterial local intestinal infusion of tacrolimus. 2000 Transplant. Proc. pmid:10995915
Sheng H et al. Ocular complications of heart transplantation in a Chinese population. 2008 Transplant. Proc. pmid:19100445
Chariat MN et al. Basiliximab in the therapy of acute rejection after organ transplantation. 2001 Transplant. Proc. pmid:11377567
Yoshimura N et al. Effectiveness of the Combination of Everolimus and Tacrolimus With High Dosage of Mizoribine for Living Donor-Related Kidney Transplantation. 2016 Transplant. Proc. pmid:27234736
Yamada MF et al. Myeloablative cord blood transplantation for adults with hematological malignancies using tacrolimus and short-term methotrexate for graft-versus-host disease prophylaxis: single-institution analysis. 2008 Transplant. Proc. pmid:19100456
Chan MC et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. 2002 Transplant. Proc. pmid:12176601
Molinaro M et al. Pharmacokinetics of tacrolimus during the early phase after heart transplantation. 2001 Transplant. Proc. pmid:11377570
Yamanaka K et al. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation. 2016 Transplant. Proc. pmid:27234735
van Riemsdijk IC et al. Improvement of cardiovascular risk factors in heart transplant recipients after conversion from cyclosporine to tacrolimus: a role of the TGF-beta system. 2002 Transplant. Proc. pmid:12176606
Pretagostini R et al. Conversion from cyclosporin to tacrolimus in chronic allograft nephropathy. 2001 Feb-Mar Transplant. Proc. pmid:11267174
Abouljoud M et al. Conversion to neoral provides effective rescue therapy for liver and kidney transplant patients intolerant of Prograf. 2001 Feb-Mar Transplant. Proc. pmid:11267175
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Takeda M et al. Pretreatment with splenectomy and FK506 in xeno-lung transplantation. 1996 Transplant. Proc. pmid:8658728
Franke GH et al. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation. 2006 Transplant. Proc. pmid:16797285
Tanaka H et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. 1987 Transplant. Proc. pmid:2445067
Berweck S et al. Clinical use of the euglycemic hyperinsulinemic clamp for diagnosis of tacrolimus-induced insulin resistance after combined pancreas-kidney transplantation. 1998 Transplant. Proc. pmid:9723345
Dikow R et al. Blood pressure profile and treatment quality in liver allograft recipients-benefit of tacrolimus versus cyclosporine. 2004 Transplant. Proc. pmid:15251373
Toyoki Y et al. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience. 2004 Transplant. Proc. pmid:15561218
Wang CH et al. Efficacy and safety of tacrolimus versus cyclosporine microemulsion in primary cardiac transplant recipients: 6-month results in Taiwan. 2004 Transplant. Proc. pmid:15561256
Heitman J et al. Antifungal effects of cyclosporine and FK 506 are mediated via immunophilin-dependent calcineurin inhibition. 1994 Transplant. Proc. pmid:7524220
Heffron TG et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. 2001 Feb-Mar Transplant. Proc. pmid:11267368
Yoshimura R et al. Effect of immunosuppressive drugs (CsA, FK 506, rapamycin) on the kidney microsomal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7524223
Groetzner J et al. Tacrolimus or cyclosporine for immunosuppression after cardiac transplantation: which treatment reveals more side effects during long-term follow-up? 2001 Feb-Mar Transplant. Proc. pmid:11267373
Liversidge J et al. FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. 1991 Transplant. Proc. pmid:1721455
Bárcena R et al. Immunosuppression in liver transplantation: a European survey. 1999 Transplant. Proc. pmid:10500654
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
Chávez R et al. Hepatotrophic effect of cyclosporine and FK 506 is not mimicked by rapamycin. 1999 Transplant. Proc. pmid:10500655
Nicholson ML et al. Is TGF-beta a profibrotic cytokine in human renal transplants? 1998 Transplant. Proc. pmid:9636384
Ginevri F et al. Expression of collagen by renal fibroblasts treated with FK 506 in vitro. 1998 Transplant. Proc. pmid:9636387
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690
Carl S et al. Combining FK 506 and mycophenolate mofetil for the treatment of acute corticosteroid-resistant rejection following kidney transplantation: a new therapeutic concept. 1998 Transplant. Proc. pmid:9636502